{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:00Z","timestamp":1792089420896,"version":"4.4.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL155281"],"award-info":[{"award-number":["R01HL155281"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Precision genetic medicine is evolving at a rapid pace and bears significant implications for clinical cardiology. Herein, we discuss the latest advancements and emerging strategies in gene therapy for cardiomyopathy and heart failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Elucidating the genetic architecture of heart failure has paved the way for precision therapies in cardiovascular medicine. Recent preclinical studies and early-phase clinical trials have demonstrated encouraging results that support the development of gene therapies for heart failure arising from a variety of etiologies. In addition to the discovery of new therapeutic targets, innovative delivery platforms are being leveraged to improve the safety and efficacy of cardiac gene therapies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Precision genetic therapy represents a potentially safe and effective approach for improving outcomes in patients with heart failure. It holds promise for radically transforming the treatment paradigm for heart failure by directly targeting the underlying etiology. As this new generation of cardiovascular medicines progress to the clinic, it is especially important to carefully evaluate the benefits and risks for patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11886-024-02096-5","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T11:07:15Z","timestamp":1723028835000},"page":"973-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Precision Genetic Therapies: Balancing Risk and Benefit in Patients with Heart Failure"],"prefix":"10.1007","volume":"26","author":[{"given":"Jamie R.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"issue":"8","key":"2096_CR1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153\u2013639.","journal-title":"Circulation"},{"issue":"17","key":"2096_CR2","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272\u201387.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"2096_CR3","doi-asserted-by":"publisher","first-page":"e012239","DOI":"10.1161\/JAHA.119.012239","volume":"8","author":"JM Kieserman","year":"2019","unstructured":"Kieserman JM, et al. Current Landscape of Heart Failure Gene Therapy. J Am Heart Assoc. 2019;8(10):e012239.","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"2096_CR4","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"9","key":"2096_CR5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.jacbts.2022.02.003","volume":"7","author":"EL Robinson","year":"2022","unstructured":"Robinson EL, Port JD. Utilization and Potential of RNA-Based Therapies in Cardiovascular Disease. JACC Basic Transl Sci. 2022;7(9):956\u201369.","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"2096_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1161\/CIRCRESAHA.117.311311","volume":"123","author":"T Lucas","year":"2018","unstructured":"Lucas T, Bonauer A, Dimmeler S. RNA Therapeutics in Cardiovascular Disease. Circ Res. 2018;123(2):205\u201320.","journal-title":"Circ Res"},{"issue":"5","key":"2096_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11883-022-01007-9","volume":"24","author":"N Bejar","year":"2022","unstructured":"Bejar N, Tat TT, Kiss DL. RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases. Curr Atheroscler Rep. 2022;24(5):307\u201321.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"2096_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.32607\/actanaturae.11063","volume":"13","author":"VV Skopenkova","year":"2021","unstructured":"Skopenkova VV, Egorova TV, Bardina MV. Muscle-Specific Promoters for Gene Therapy. Acta Naturae. 2021;13(1):47\u201358.","journal-title":"Acta Naturae"},{"issue":"4","key":"2096_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, et al. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs. 2017;31(4):317\u201334.","journal-title":"BioDrugs"},{"issue":"6","key":"2096_CR10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/CIRCRESAHA.113.300282","volume":"113","author":"TJ Cahill","year":"2013","unstructured":"Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013;113(6):660\u201375.","journal-title":"Circ Res"},{"issue":"1","key":"2096_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jacbts.2021.07.012","volume":"7","author":"AS Helms","year":"2022","unstructured":"Helms AS, Thompson AD, Day SM. Translation of New and Emerging Therapies for Genetic Cardiomyopathies. JACC Basic Transl Sci. 2022;7(1):70\u201383.","journal-title":"JACC Basic Transl Sci"},{"issue":"6629","key":"2096_CR12","doi-asserted-by":"publisher","first-page":"eadd864","DOI":"10.1126\/science.add8643","volume":"379","author":"JY Wang","year":"2023","unstructured":"Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science. 2023;379(6629):eadd864.","journal-title":"Science"},{"issue":"1\u20132","key":"2096_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2015.12.035","volume":"164","author":"AV Wright","year":"2016","unstructured":"Wright AV, Nunez JK, Doudna JA. Biology and Applications of CRISPR Systems: Harnessing Nature\u2019s Toolbox for Genome Engineering. Cell. 2016;164(1\u20132):29\u201344.","journal-title":"Cell"},{"issue":"12","key":"2096_CR14","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41556-019-0425-z","volume":"21","author":"CD Yeh","year":"2019","unstructured":"Yeh CD, Richardson CD, Corn JE. Advances in genome editing through control of DNA repair pathways. Nat Cell Biol. 2019;21(12):1468\u201378.","journal-title":"Nat Cell Biol"},{"issue":"7785","key":"2096_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149\u201357.","journal-title":"Nature"},{"issue":"7681","key":"2096_CR16","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli NM, et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464\u201371.","journal-title":"Nature"},{"issue":"8","key":"2096_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41569-021-00669-3","volume":"19","author":"M Nishiga","year":"2022","unstructured":"Nishiga M, et al. The use of new CRISPR tools in cardiovascular research and medicine. Nat Rev Cardiol. 2022;19(8):505\u201321.","journal-title":"Nat Rev Cardiol"},{"key":"2096_CR18","doi-asserted-by":"publisher","first-page":"1138596","DOI":"10.3389\/fbioe.2023.1138596","volume":"11","author":"R Ewaisha","year":"2023","unstructured":"Ewaisha R, Anderson KS. Immunogenicity of CRISPR therapeutics-Critical considerations for clinical translation. Front Bioeng Biotechnol. 2023;11:1138596.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"2096_CR19","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ymthe.2020.05.007","volume":"28","author":"V Gough","year":"2020","unstructured":"Gough V, Gersbach CA. Immunity to Cas9 as an Obstacle to Persistent Genome Editing. Mol Ther. 2020;28(6):1389\u201391.","journal-title":"Mol Ther"},{"issue":"1","key":"2096_CR20","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","volume":"12","author":"CH Hakim","year":"2021","unstructured":"Hakim CH, et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat Commun. 2021;12(1):6769.","journal-title":"Nat Commun"},{"issue":"3","key":"2096_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert LA, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159(3):647\u201361.","journal-title":"Cell"},{"issue":"5","key":"2096_CR22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","volume":"152","author":"LS Qi","year":"2013","unstructured":"Qi LS, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173\u201383.","journal-title":"Cell"},{"issue":"1","key":"2096_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cell.2016.08.056","volume":"167","author":"XS Liu","year":"2016","unstructured":"Liu XS, et al. Editing DNA Methylation in the Mammalian Genome. Cell. 2016;167(1):233-247 e17.","journal-title":"Cell"},{"issue":"1","key":"2096_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2016.09.006","volume":"167","author":"A Amabile","year":"2016","unstructured":"Amabile A, et al. Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. Cell. 2016;167(1):219-232 e14.","journal-title":"Cell"},{"issue":"5","key":"2096_CR25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nbt.3199","volume":"33","author":"IB Hilton","year":"2015","unstructured":"Hilton IB, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat Biotechnol. 2015;33(5):510\u20137.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2096_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nmeth.3325","volume":"12","author":"NA Kearns","year":"2015","unstructured":"Kearns NA, et al. Functional annotation of native enhancers with a Cas9-histone demethylase fusion. Nat Methods. 2015;12(5):401\u20133.","journal-title":"Nat Methods"},{"issue":"1","key":"2096_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther. 2022;7(1):166.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2096_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.14797\/mdcvj.1169","volume":"18","author":"JP Cooke","year":"2022","unstructured":"Cooke JP, Youker KA. Future Impact of mRNA Therapy on Cardiovascular Diseases. Methodist Debakey Cardiovasc J. 2022;18(5):64\u201373.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"3","key":"2096_CR29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","volume":"31","author":"V Anttila","year":"2023","unstructured":"Anttila V, et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol Ther. 2023;31(3):866\u201374.","journal-title":"Mol Ther"},{"issue":"6576","key":"2096_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136.","journal-title":"Science"},{"issue":"10","key":"2096_CR31","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1161\/CIRCRESAHA.120.315855","volume":"126","author":"A Cannata","year":"2020","unstructured":"Cannata A, et al. Gene Therapy for the Heart Lessons Learned and Future Perspectives. Circ Res. 2020;126(10):1394\u2013414.","journal-title":"Circ Res"},{"issue":"1","key":"2096_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/cvr\/cvv205","volume":"108","author":"MY Rincon","year":"2015","unstructured":"Rincon MY, VandenDriessche T, Chuah MK. Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res. 2015;108(1):4\u201320.","journal-title":"Cardiovasc Res"},{"issue":"2","key":"2096_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0298-180","volume":"18","author":"G Schiedner","year":"1998","unstructured":"Schiedner G, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 1998;18(2):180\u20133.","journal-title":"Nat Genet"},{"issue":"1\u20132","key":"2096_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"SE Raper","year":"2003","unstructured":"Raper SE, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1\u20132):148\u201358.","journal-title":"Mol Genet Metab"},{"key":"2096_CR35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","volume":"4","author":"R Calcedo","year":"2013","unstructured":"Calcedo R, Wilson JM. Humoral Immune Response to AAV. Front Immunol. 2013;4:341.","journal-title":"Front Immunol"},{"key":"2096_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","volume":"11","author":"G Ronzitti","year":"2020","unstructured":"Ronzitti G, Gross DA, Mingozzi F. Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. Front Immunol. 2020;11:670.","journal-title":"Front Immunol"},{"issue":"3","key":"2096_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, et al. Immune Responses to Viral Gene Therapy Vectors. Mol Ther. 2020;28(3):709\u201322.","journal-title":"Mol Ther"},{"key":"2096_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","volume":"25","author":"JR Mendell","year":"2022","unstructured":"Mendell JR, et al. Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations. Mol Ther Methods Clin Dev. 2022;25:74\u201383.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2096_CR39","doi-asserted-by":"publisher","first-page":"952755","DOI":"10.3389\/fcvm.2022.952755","volume":"9","author":"H Zhang","year":"2022","unstructured":"Zhang H, et al. AAV-mediated gene therapy: Advancing cardiovascular disease treatment. Front Cardiovasc Med. 2022;9:952755.","journal-title":"Front Cardiovasc Med"},{"issue":"19","key":"2096_CR40","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar M, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184(19):4919-4938 e22.","journal-title":"Cell"},{"issue":"1","key":"2096_CR41","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","volume":"11","author":"J Weinmann","year":"2020","unstructured":"Weinmann J, et al. Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun. 2020;11(1):5432.","journal-title":"Nat Commun"},{"issue":"19","key":"2096_CR42","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1016\/j.cell.2021.08.031","volume":"184","author":"CG Bonnemann","year":"2021","unstructured":"Bonnemann CG. Designer AAV muscle up. Cell. 2021;184(19):4845\u20137.","journal-title":"Cell"},{"issue":"2","key":"2096_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nmeth.2331","volume":"10","author":"M Ranzani","year":"2013","unstructured":"Ranzani M, et al. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods. 2013;10(2):155\u201361.","journal-title":"Nat Methods"},{"issue":"6","key":"2096_CR44","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/gt.2012.88","volume":"20","author":"C Papayannakos","year":"2013","unstructured":"Papayannakos C, Daniel R. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. Gene Ther. 2013;20(6):581\u20138.","journal-title":"Gene Ther"},{"issue":"12","key":"2096_CR45","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"R Zufferey","year":"1998","unstructured":"Zufferey R, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873\u201380.","journal-title":"J Virol"},{"issue":"1","key":"2096_CR46","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12951-023-02044-5","volume":"21","author":"C Wang","year":"2023","unstructured":"Wang C, et al. Emerging non-viral vectors for gene delivery. J Nanobiotechnology. 2023;21(1):272.","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"2096_CR47","first-page":"GE01","volume":"9","author":"M Ramamoorth","year":"2015","unstructured":"Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res. 2015;9(1):GE01-6.","journal-title":"J Clin Diagn Res"},{"issue":"5","key":"2096_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23(5):265\u201380.","journal-title":"Nat Rev Genet"},{"key":"2096_CR49","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, et al. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm. 2021;601:120586.","journal-title":"Int J Pharm"},{"issue":"1","key":"2096_CR50","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei T, et al. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):3232.","journal-title":"Nat Commun"},{"key":"2096_CR51","doi-asserted-by":"publisher","first-page":"673286","DOI":"10.3389\/fgene.2021.673286","volume":"12","author":"L Duan","year":"2021","unstructured":"Duan L, et al. Nanoparticle Delivery of CRISPR\/Cas9 for Genome Editing. Front Genet. 2021;12:673286.","journal-title":"Front Genet"},{"key":"2096_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/TACG.S171481","volume":"12","author":"J Finsterer","year":"2019","unstructured":"Finsterer J. Barth syndrome: mechanisms and management. Appl Clin Genet. 2019;12:95\u2013106.","journal-title":"Appl Clin Genet"},{"issue":"4","key":"2096_CR53","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/genes13040656","volume":"13","author":"J Pang","year":"2022","unstructured":"Pang J, et al. Barth Syndrome Cardiomyopathy: An Update. Genes (Basel). 2022;13(4):656.","journal-title":"Genes (Basel)"},{"issue":"6","key":"2096_CR54","doi-asserted-by":"publisher","first-page":"H2255","DOI":"10.1152\/ajpheart.00873.2020","volume":"320","author":"AA Greenwell","year":"2021","unstructured":"Greenwell AA, et al. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation. Am J Physiol Heart Circ Physiol. 2021;320(6):H2255\u201369.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2096_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jimd.12453","volume":"45","author":"R Thompson","year":"2022","unstructured":"Thompson R, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17\u201328.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"2096_CR56","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/CIRCRESAHA.119.315956","volume":"126","author":"S Wang","year":"2020","unstructured":"Wang S, et al. AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome. Circ Res. 2020;126(8):1024\u201339.","journal-title":"Circ Res"},{"issue":"5","key":"2096_CR57","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/CIRCHEARTFAILURE.114.001105","volume":"7","author":"RS D\u2019Souza","year":"2014","unstructured":"D\u2019Souza RS, et al. Danon disease: clinical features, evaluation, and management. Circ Heart Fail. 2014;7(5):843\u20139.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"2096_CR58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/GIM.0b013e31820ad795","volume":"13","author":"D Boucek","year":"2011","unstructured":"Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011;13(6):563\u20138.","journal-title":"Genet Med"},{"issue":"10","key":"2096_CR59","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s10038-007-0184-8","volume":"52","author":"MRG Taylor","year":"2007","unstructured":"Taylor MRG, et al. Danon disease presenting with dilated cardiomyopathy and a complex phenotype. J Hum Genet. 2007;52(10):830\u20135.","journal-title":"J Hum Genet"},{"issue":"11","key":"2096_CR60","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.105.546481","volume":"112","author":"Z Yang","year":"2005","unstructured":"Yang Z, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112(11):1612\u20137.","journal-title":"Circulation"},{"issue":"8","key":"2096_CR61","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/hrt.2003.029504","volume":"90","author":"P Charron","year":"2004","unstructured":"Charron P, et al. Danon\u2019s disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90(8):842\u20136.","journal-title":"Heart"},{"key":"2096_CR62","doi-asserted-by":"publisher","unstructured":"Manso AM, et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease. Sci Transl Med. 2020;12(535):eaax1744. https:\/\/doi.org\/10.1126\/scitranslmed.aax1744.","DOI":"10.1126\/scitranslmed.aax1744"},{"issue":"2","key":"2096_CR63","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2015.01.013","volume":"21","author":"EM McNally","year":"2015","unstructured":"McNally EM, Barefield DY, Puckelwartz MJ. The genetic landscape of cardiomyopathy and its role in heart failure. Cell Metab. 2015;21(2):174\u201382.","journal-title":"Cell Metab"},{"key":"2096_CR64","doi-asserted-by":"publisher","first-page":"972301","DOI":"10.3389\/fcvm.2022.972301","volume":"9","author":"LK Keyt","year":"2022","unstructured":"Keyt LK, et al. Thin filament cardiomyopathies: A review of genetics, disease mechanisms, and emerging therapeutics. Front Cardiovasc Med. 2022;9:972301.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2096_CR65","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","volume":"29","author":"AC Chai","year":"2023","unstructured":"Chai AC, et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice. Nat Med. 2023;29(2):401\u201311.","journal-title":"Nat Med"},{"issue":"2","key":"2096_CR66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","volume":"29","author":"D Reichart","year":"2023","unstructured":"Reichart D, et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023;29(2):412\u201321.","journal-title":"Nat Med"},{"key":"2096_CR67","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.1038\/ncomms6515","volume":"5","author":"G Mearini","year":"2014","unstructured":"Mearini G, et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat Commun. 2014;5:5515.","journal-title":"Nat Commun"},{"issue":"20","key":"2096_CR68","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.jacc.2018.08.2181","volume":"72","author":"F Dominguez","year":"2018","unstructured":"Dominguez F, et al. Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations. J Am Coll Cardiol. 2018;72(20):2471\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2096_CR69","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10741-015-9487-6","volume":"20","author":"T Knezevic","year":"2015","unstructured":"Knezevic T, et al. BAG3: a new player in the heart failure paradigm. Heart Fail Rev. 2015;20(4):423\u201334.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"2096_CR70","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1038\/s41467-021-23272-z","volume":"12","author":"TG Martin","year":"2021","unstructured":"Martin TG, et al. Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover. Nat Commun. 2021;12(1):2942.","journal-title":"Nat Commun"},{"issue":"23","key":"2096_CR71","doi-asserted-by":"publisher","first-page":"e027373","DOI":"10.1161\/JAHA.122.027373","volume":"11","author":"HQ Qu","year":"2022","unstructured":"Qu HQ, Feldman AM, Hakonarson H. Genetics of BAG3: A Paradigm for Developing Precision Therapies for Dilated Cardiomyopathies. J Am Heart Assoc. 2022;11(23):e027373.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"2096_CR72","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamacardio.2018.2541","volume":"3","author":"VD Myers","year":"2018","unstructured":"Myers VD, et al. Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiol. 2018;3(10):929\u201338.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"2096_CR73","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jacbts.2016.08.008","volume":"1","author":"T Knezevic","year":"2016","unstructured":"Knezevic T, et al. Adeno-associated Virus Serotype 9 - Driven Expression of BAG3 Improves Left Ventricular Function in Murine Hearts with Left Ventricular Dysfunction Secondary to a Myocardial Infarction. JACC Basic Transl Sci. 2016;1(7):647\u201356.","journal-title":"JACC Basic Transl Sci"},{"issue":"9","key":"2096_CR74","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jacbts.2022.04.002","volume":"7","author":"VD Myers","year":"2022","unstructured":"Myers VD, et al. Cardiac Transduction in Mini-Pigs After Low-Dose Retrograde Coronary Sinus Infusion of AAV9-BAG3: A Pilot Study. JACC Basic Transl Sci. 2022;7(9):951\u20133.","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"2096_CR75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.","journal-title":"Nat Rev Dis Primers"},{"key":"2096_CR76","unstructured":"Venugopal V, Pavlakis S. Duchenne muscular dystrophy. In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"issue":"s2","key":"2096_CR77","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.3233\/JND-210678","volume":"8","author":"N Elangkovan","year":"2021","unstructured":"Elangkovan N, Dickson G. Gene Therapy for Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021;8(s2):S303\u201316.","journal-title":"J Neuromuscul Dis"},{"issue":"14","key":"2096_CR78","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Delandistrogene Moxeparvovec: First Approval. Drugs. 2023;83(14):1323\u20139.","journal-title":"Drugs"},{"issue":"8","key":"2096_CR79","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections. Nat Rev Drug Discov. 2023;22(8):610.","journal-title":"Nat Rev Drug Discov"},{"key":"2096_CR80","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.omtn.2023.04.009","volume":"32","author":"AC Chai","year":"2023","unstructured":"Chai AC, et al. Single-swap editing for the correction of common Duchenne muscular dystrophy mutations. Mol Ther Nucleic Acids. 2023;32:522\u201335.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2096_CR81","doi-asserted-by":"publisher","unstructured":"Chemello F, et al.\u00a0Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv. 2021;7(18):eabg4910. https:\/\/doi.org\/10.1126\/sciadv.abg4910.","DOI":"10.1126\/sciadv.abg4910"},{"key":"2096_CR82","doi-asserted-by":"publisher","unstructured":"Happi Mbakam C, et al.\u00a0Prime editing permits the introduction of specific mutations in the gene responsible for Duchenne muscular dystrophy. Int J Mol Sci. 2022;23(11):6160. https:\/\/doi.org\/10.3390\/ijms23116160.","DOI":"10.3390\/ijms23116160"},{"key":"2096_CR83","doi-asserted-by":"publisher","unstructured":"Johnston JR, McNally EM. Genetic correction strategies for Duchenne muscular dystrophy and their impact on the heart. Prog Pediatr Cardiol. 2021;63:101460. https:\/\/doi.org\/10.1016\/j.ppedcard.2021.101460.","DOI":"10.1016\/j.ppedcard.2021.101460"},{"key":"2096_CR84","unstructured":"Bokhari SRA, Zulfiqar H, Hariz A. Fabry disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"key":"2096_CR85","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.15420\/cfr.2023.06","volume":"9","author":"E Monda","year":"2023","unstructured":"Monda E, et al. Cardiovascular Involvement in Fabry\u2019s Disease: New Advances in Diagnostic Strategies, Outcome Prediction and Management. Card Fail Rev. 2023;9:e12.","journal-title":"Card Fail Rev"},{"issue":"7","key":"2096_CR86","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, et al. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(7):922\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2096_CR87","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s13023-023-02894-0","volume":"18","author":"M Deng","year":"2023","unstructured":"Deng M, et al. Systematic gene therapy derived from an investigative study of AAV2\/8 vector gene therapy for Fabry disease. Orphanet J Rare Dis. 2023;18(1):275.","journal-title":"Orphanet J Rare Dis"},{"key":"2096_CR88","unstructured":"Jain A, Zahra F. Transthyretin amyloid cardiomyopathy (ATTR-CM). In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"issue":"1","key":"2096_CR89","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation. 2020;142(1):e7\u201322.","journal-title":"Circulation"},{"issue":"10","key":"2096_CR90","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"A Aimo","year":"2022","unstructured":"Aimo A, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022;19(10):655\u201367.","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"2096_CR91","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn JD, et al. A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Rep. 2018;22(9):2227\u201335.","journal-title":"Cell Rep"},{"issue":"6","key":"2096_CR92","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021;385(6):493\u2013502.","journal-title":"N Engl J Med"},{"issue":"14","key":"2096_CR93","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.3390\/jcm12144769","volume":"12","author":"C Bouchard","year":"2023","unstructured":"Bouchard C, Tremblay JP. Limb-Girdle Muscular Dystrophies Classification and Therapies. J Clin Med. 2023;12(14):4769.","journal-title":"J Clin Med"},{"issue":"3","key":"2096_CR94","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/00001573-199705000-00015","volume":"12","author":"GF Cox","year":"1997","unstructured":"Cox GF, Kunkel LM. Dystrophies and heart disease. Curr Opin Cardiol. 1997;12(3):329\u201343.","journal-title":"Curr Opin Cardiol"},{"issue":"5","key":"2096_CR95","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26014","volume":"57","author":"NJ Silvestri","year":"2018","unstructured":"Silvestri NJ, et al. Cardiac involvement in the muscular dystrophies. Muscle Nerve. 2018;57(5):707\u201315.","journal-title":"Muscle Nerve"},{"issue":"17","key":"2096_CR96","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1212\/WNL.0000000000001519","volume":"84","author":"C Semplicini","year":"2015","unstructured":"Semplicini C, et al. Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E. Neurology. 2015;84(17):1772\u201381.","journal-title":"Neurology"},{"key":"2096_CR97","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.omtm.2023.03.004","volume":"29","author":"H Hermann","year":"2023","unstructured":"Hermann H, Wuebbles RD, Burkin DJ. A gene therapy approach for the treatment of limb-girdle muscular dystrophy 2C\/R5. Mol Ther Methods Clin Dev. 2023;29:160\u20131.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2096_CR98","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.omtm.2023.01.004","volume":"28","author":"YE Seo","year":"2023","unstructured":"Seo YE, et al. Systemic gamma-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C\/R5 mouse model. Mol Ther Methods Clin Dev. 2023;28:284\u201399.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2096_CR99","unstructured":"Sakuru R. Bollu PC. Hurler syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"issue":"12","key":"2096_CR100","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/bloodadvances.2020001708","volume":"4","author":"BTA van den Broek","year":"2020","unstructured":"van den Broek BTA, et al. Hurdles in treating Hurler disease: potential routes to achieve a \u201creal\u201d cure. Blood Adv. 2020;4(12):2837\u201349.","journal-title":"Blood Adv"},{"key":"2096_CR101","doi-asserted-by":"publisher","first-page":"965089","DOI":"10.3389\/fmolb.2022.965089","volume":"9","author":"SR Wood","year":"2022","unstructured":"Wood SR, Bigger BW. Delivering gene therapy for mucopolysaccharide diseases. Front Mol Biosci. 2022;9:965089.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2096_CR102","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1038\/s41467-021-24443-8","volume":"12","author":"SK Bose","year":"2021","unstructured":"Bose SK, et al. In utero adenine base editing corrects multi-organ pathology in a lethal lysosomal storage disease. Nat Commun. 2021;12(1):4291.","journal-title":"Nat Commun"},{"key":"2096_CR103","unstructured":"Salik I, Rawla P. Marfan syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"key":"2096_CR104","doi-asserted-by":"publisher","unstructured":"Kallenbach K, et al.\u00a0Translational medicine: towards gene therapy of Marfan Syndrome. J Clin Med. 2022;11(14):3934. https:\/\/doi.org\/10.3390\/jcm11143934.","DOI":"10.3390\/jcm11143934"},{"issue":"11","key":"2096_CR105","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.ymthe.2018.08.007","volume":"26","author":"Y Zeng","year":"2018","unstructured":"Zeng Y, et al. Correction of the Marfan Syndrome Pathogenic FBN1 Mutation by Base Editing in Human Cells and Heterozygous Embryos. Mol Ther. 2018;26(11):2631\u20137.","journal-title":"Mol Ther"},{"key":"2096_CR106","unstructured":"Sickles CK, Gross GP. Progeria. In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"issue":"7843","key":"2096_CR107","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","volume":"589","author":"LW Koblan","year":"2021","unstructured":"Koblan LW, et al. In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice. Nature. 2021;589(7843):608\u201314.","journal-title":"Nature"},{"key":"2096_CR108","unstructured":"Williams CT, De Jesus O. Friedreich Ataxia. In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"issue":"2","key":"2096_CR109","doi-asserted-by":"publisher","first-page":"NS20200093","DOI":"10.1042\/NS20200093","volume":"5","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Farmer G. Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal Signal. 2021;5(2):NS20200093.","journal-title":"Neuronal Signal"},{"issue":"5","key":"2096_CR110","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","volume":"20","author":"M Perdomini","year":"2014","unstructured":"Perdomini M, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia. Nat Med. 2014;20(5):542\u20137.","journal-title":"Nat Med"},{"issue":"15\u201316","key":"2096_CR111","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1089\/hum.2019.363","volume":"31","author":"CO Salami","year":"2020","unstructured":"Salami CO, et al. Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich\u2019s Ataxia Corrected by AAV-mediated Gene Therapy. Hum Gene Ther. 2020;31(15\u201316):819\u201327.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"2096_CR112","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/ijms22041815","volume":"22","author":"G Ocana-Santero","year":"2021","unstructured":"Ocana-Santero G, Diaz-Nido J, Herranz-Martin S. Future Prospects of Gene Therapy for Friedreich\u2019s Ataxia. Int J Mol Sci. 2021;22(4):1815.","journal-title":"Int J Mol Sci"},{"key":"2096_CR113","unstructured":"Rajkumar V, Dumpa V. Lysosomal storage disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing;\u00a02023."},{"issue":"11","key":"2096_CR114","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","volume":"24","author":"D Stevens","year":"2022","unstructured":"Stevens D, Milani-Nejad S, Mozaffar T. Pompe Disease: a Clinical, Diagnostic, and Therapeutic Overview. Curr Treat Options Neurol. 2022;24(11):573\u201388.","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"2096_CR115","doi-asserted-by":"publisher","first-page":"e13968","DOI":"10.15252\/emmm.202113968","volume":"14","author":"M Eggers","year":"2022","unstructured":"Eggers M, et al. Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity. EMBO Mol Med. 2022;14(1):e13968.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"2096_CR116","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","volume":"31","author":"EC Smith","year":"2023","unstructured":"Smith EC, et al. Phase I study of liver depot gene therapy in late-onset Pompe disease. Mol Ther. 2023;31(7):1994\u20132004.","journal-title":"Mol Ther"},{"key":"2096_CR117","doi-asserted-by":"publisher","unstructured":"Vora N, et al.\u00a0Gene therapy for heart failure: a novel treatment for the age old disease. Dis Mon. 2023;70(2):101636. https:\/\/doi.org\/10.1016\/j.disamonth.2023.101636.","DOI":"10.1016\/j.disamonth.2023.101636"},{"key":"2096_CR118","doi-asserted-by":"crossref","unstructured":"Argiro A, Ding J, Adler E.\u00a0Gene therapy for heart failure and cardiomyopathies. Rev Esp Cardiol (Engl Ed). 2023;76(12):1042\u20131054","DOI":"10.1016\/j.rec.2023.06.009"},{"issue":"13","key":"2096_CR119","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek A, et al. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy. N Engl J Med. 2023;389(13):1203\u201310.","journal-title":"N Engl J Med"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02096-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-024-02096-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-024-02096-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T11:55:01Z","timestamp":1725623701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-024-02096-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":119,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s11886-024-02096-5","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"2 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jamie Johnston was formerly employed at Kate Therapeutics and reports owning stock or stock options. Eric Adler is the Chief Scientific Officer at Lexeo Therapeutics and a shareholder in Rocket Pharmaceuticals. He also reports the following: consulting fees from Abiomed and Abbott; payment for expert testimony from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board for Rocket Pharmaceuticals, Cytokinetics, and Kiniska; leadership or fiduciary role in Lexeo Therapeutics, Heart Failure Society of America, and American Heart Association; and stock or stock options for Lexeo Therapeutics, Rocket Pharmaceuticals, and Papillion Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Jamie Johnston was formerly employed at Kate Therapeutics and reports owning stock or stock options. Eric Adler is the Chief Scientific Officer at Lexeo Therapeutics and a shareholder in Rocket Pharmaceuticals. He also reports the following: consulting fees from Abiomed and Abbott; payment for expert testimony from AstraZeneca; participation on a Data Safety Monitoring Board or Advisory Board for Rocket Pharmaceuticals, Cytokinetics, and Kiniska; leadership or fiduciary role in Lexeo Therapeutics, Heart Failure Society of America, and American Heart Association; and stock or stock options for Lexeo Therapeutics, Rocket Pharmaceuticals, and Papillion Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}